AstraZeneca has received Food And Drug Administration approval for one product, and entered into a deal to sell the U.S. rights to another. The FDA granted marketing approval to Bevespi Aerosphere, a maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.
{iframe}http://www.bizjournals.com/philadelphia/morning_roundup/2016/04/astrazeneca-fda-approval-copd-drug-zurampic.html?ana=e_phil_rdup&s=newsletter&ed=2016-04-26&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1461683584&j=72671152{/iframe}